Blood Cell Profiles as Predictors of Treatment Response and Outcomes in Neoadjuvant Immunotherapy with Chemotherapy for Esophageal Squamous Cell Carcinoma - Report - MDSpire
Advertisement
Blood Cell Profiles as Predictors of Treatment Response and Outcomes in Neoadjuvant Immunotherapy with Chemotherapy for Esophageal Squamous Cell Carcinoma
Clinical Report: Blood Cell Profiles as Predictors of Treatment Response
Overview
This study investigates the predictive value of specific blood parameters, such as neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR), in patients with esophageal squamous cell carcinoma (ESCC) undergoing neoadjuvant immunotherapy combined with chemotherapy. Findings suggest that these blood parameters may serve as indicators of treatment efficacy and patient outcomes.
Background
Esophageal cancer, particularly squamous cell carcinoma, is a leading cause of cancer-related mortality worldwide. Neoadjuvant therapy, combining immunotherapy and chemotherapy, has emerged as a standard treatment for locally advanced cases. Identifying reliable predictors of treatment response is crucial for optimizing patient management and improving survival rates.
Data Highlights
The study includes findings related to blood parameters and their correlation with treatment response.
Key Findings
91 patients with clinical stage II–IVA ESCC were included in the study.
Neoadjuvant immunotherapy combined with chemotherapy was administered using sintilimab.
Postoperative pathological complete response (PCR) was the primary therapeutic response measured.
Indicators such as neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were explored for their prognostic value.
High pretreatment red cell distribution widths correlated with poor survival outcomes.
Demographics and clinical characteristics of the patient cohort were recorded.
Clinical Implications
Healthcare professionals should consider the evaluation of peripheral blood cell profiles, such as NLR and PLR, as potential prognostic indicators in patients receiving neoadjuvant therapy for ESCC. This could enhance treatment personalization and improve patient outcomes by tailoring therapies based on individual blood profile assessments.
Conclusion
The study highlights the importance of blood cell profiles in predicting treatment response in ESCC, suggesting a need for further research to validate these findings in clinical practice and explore their integration into treatment protocols.
